#161210

MCF10A-AKTm-1 cell line

Cat. #161210

MCF10A-AKTm-1 cell line

Cat. #: 161210

Sub-type: Continuous

Organism: Human

Tissue: Mammarygland epithelium

Model: Mutant

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Medical-Industrial Translational Research Center

Institute: Fukushima Medical University

Tool Details
Target Details
Applications
Handling

Tool Details

*FOR RESEARCH USE ONLY

  • Name: MCF10A-AKTm-1 cell line
  • Alternate name: 06M09003
  • Cancers detailed: Non-tumorigenic
  • Research fields: Cancer;Cell biology
  • Tool sub type: Continuous
  • Parental cell: MCF10A, a non-tumorigenic cell line from human mammarygland epithelium
  • Clone: AKT1_type-02
  • Organism: Human
  • Tissue: Mammarygland epithelium
  • Morphology: Epithelial
  • Growth properties: Adherent
  • Model: Mutant
  • Model description: Type-02; Type mutation: E17K; CDS mutation: c.49G>A; AA mutation: p.E17K; COSMIC Mutation ID: COSM33765
  • Description: Non-tumorigenic immortalized breast epithelial cell stably overexpressing mutant cancer-related gene, AKT1 (AKT serine/threonine kinase 1). AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers.The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.
  • Application: Functional analysis of mutated genes, Drug screening
  • Biosafety level: 1

Target Details

  • Target: AKT serine/threonine kinase 1 [AKT1]
  • Target background: Gene ID: 207; References: DNA (mRNA): NM_005163.2; Protein: NP_005154.2

Applications

  • Application: Functional analysis of mutated genes, Drug screening

Handling

  • Format: Frozen
  • Growth medium: DMEM/Ham's F-12 supplemented with 5% heat-inactivated horse serum, 10 Â?g/ml insulin (human, recombinant), 5 Â?M forskolin, 0.5 Â?g/ml hydrocortisone, 20 ng/ml EGF (human, recombinant), 100 U/ml penicillin, and 100 Â?g/ml streptomycin
  • Temperature: 37° C
  • Atmosphere: Humidified incubator with 5% CO2
  • Shipping conditions: Dry ice
  • Storage medium: CELLBANKER 2 (Zenogen pharma)
  • Storage conditions: Liquid Nitrogen
  • Initial handling information: Thaw the vial at 37 °C in a water bath?then seed cells into a T75 flask. Culture in a humidified Incubator at 37 ? with 5% CO2 in air. Culture medium should be changed every 2 to 3 days.
  • Cultured in antibiotics: 100 U/ml Penicillin, and 100 Â?g/ml Streptomycin
  • Mycoplasma free: Yes
  • Characterisation tests: Comprehensive gene expression analysis; Identification of cell proliferation and cellular form; Drug sensitivity tests